Web Results

ltd.aruplab.com/Tests/Pub/2001601

RNA polymerase III IgG antibody occur in about 11-23 percent of SSc patients, and typically in the absence of anti-centromere and anti-Scl-70 antibodies. A negative result indicates no detectable IgG antibodies to the dominant antigen of RNA polymerase III and does not rule out the possibility of SSc.

www.healthcare.uiowa.edu/path_handbook/handbook/test2949.html

A positive result indicates the presence of measurable IgG antibodies to RNA polymerase III, but does not unequivocally establish the diagnosis of systemic sclerosis or other autoimmune disease. The level of RNA polymerase III autoantibodies does not indicate the severity of disease in patients with systemic sclerosis.

testdirectory.questdiagnostics.com/.../19899/rna-polymerase-iii-antibody?cc=MASTER

RNA Polymerase III Antibody. Test Code. 19899. CPT Code(s) 83516. Print. Test Code. 19899. CPT Code(s) 83516. Not offered in Quest Infectious Disease Inc. - San Juan Capistrano, CA. Please provide SERVICE AREA INFORMATION to confirm Test Code for the lab that services your account or to find available tests you can order.

www.aruplab.com/guides/ug/tests/2001601.jsp

RNA polymerase III IgG antibody occur in about 11-23 percent of SSc patients, and typically in the absence of anti-centromere and anti-Scl-70 antibodies. A negative result indicates no detectable IgG antibodies to the dominant antigen of RNA polymerase III and does not rule out the possibility of SSc.

www.inspire.com/groups/scleroderma-foundation/discussion/rna-polymerase-iii...

In addition to SRC, RNA Pol III antibody also has a temporal relationship to cancers (plus or minus one year). Some (e.g., some researchers at Johns Hopkins) believe that RNA pol III scleroderma is a paraneoplastic syndrome (a response to cancer, which may or may not be diagnosed).

en.wikipedia.org/wiki/RNA_polymerase_III

In eukaryote cells, RNA polymerase III (also called Pol III) transcribes DNA to synthesize ribosomal 5S rRNA, tRNA and other small RNAs. The genes transcribed by RNA Pol III fall in the category of "housekeeping" genes whose expression is required in all cell types and most environmental conditions.

www.ncbi.nlm.nih.gov/pmc/articles/PMC2430219

To evaluate the analytical performance of an ELISA for the detection of anti-RNA polymerase III antibody (ARA) and to assess IIF as a method for identifying this antibody. Methods. A commercially available ELISA was used to assess the presence of ARA in sera from 1018 SSc patients.

www.ncbi.nlm.nih.gov/pmc/articles/PMC1905338

There are three classes of RNA polymerase enzyme (RNAPs I, II and III). In systemic sclerosis (SSc), three main groups of anti-RNAP sera have been characterized by radioimmunoprecipitation techniques: anti-RNAP I/III sera, anti-RNAP I/II/III sera, and a group precipitating both RNAP II and topoisomerase I (topo I).

www.jrheum.org/content/44/5/550

The presence of circulating antinuclear antibodies (ANA) is one of the distinctive features of systemic sclerosis (SSc), or scleroderma. A variety of SSc-related ANA, including anticentromere antibody (ACA), antitopoisomerase I antibody (anti–topo I), and anti-RNA polymerase (RNAP) III antibody, have been well characterized and are used in our daily clinical practice. They are specific to ...

sclerodermainfo.org/faq/scleroderma-antibodies

Several studies have shown that there is clear clinical relevance based on the specific antibody type. Different antibodies have very different risk profiles. For example, with RNA Polymerase III antibodies, there is a significantly increased risk of kidney involvement early in the disease process.